California Public Employees Retirement System trimmed its stake in PerkinElmer, Inc. (NYSE:PKI) by 0.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 275,500 shares of the medical research company’s stock after selling 100 shares during the quarter. California Public Employees Retirement System owned approximately 0.25% of PerkinElmer worth $18,773,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Envestnet Asset Management Inc. lifted its stake in PerkinElmer by 28.1% in the first quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock valued at $115,000 after buying an additional 434 shares during the last quarter. Acrospire Investment Management LLC lifted its stake in PerkinElmer by 185.7% in the second quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,300 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in PerkinElmer in the first quarter valued at $152,000. LS Investment Advisors LLC lifted its stake in PerkinElmer by 2.1% in the second quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock valued at $196,000 after buying an additional 60 shares during the last quarter. Finally, Capital Asset Advisory Services LLC bought a new stake in PerkinElmer in the second quarter valued at $222,000. Institutional investors own 91.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/california-public-employees-retirement-system-sells-100-shares-of-perkinelmer-inc-pki/1600860.html.

PerkinElmer, Inc. (PKI) opened at 68.97 on Friday. PerkinElmer, Inc. has a one year low of $45.35 and a one year high of $70.16. The stock’s 50 day moving average price is $66.08 and its 200-day moving average price is $63.21. The firm has a market capitalization of $7.60 billion, a price-to-earnings ratio of 20.80 and a beta of 0.74.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $547.00 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The business’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. On average, equities research analysts anticipate that PerkinElmer, Inc. will post $2.89 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Shareholders of record on Friday, October 20th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s dividend payout ratio is currently 8.46%.

A number of equities research analysts have issued reports on the company. Cowen and Company reiterated a “market perform” rating and issued a $70.00 target price (up from $61.00) on shares of PerkinElmer in a research note on Tuesday, June 20th. Wells Fargo & Company assumed coverage on PerkinElmer in a research note on Thursday, July 13th. They issued a “market perform” rating and a $72.00 target price on the stock. Zacks Investment Research cut PerkinElmer from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $67.00 target price on shares of PerkinElmer in a research note on Tuesday, September 26th. Finally, BidaskClub cut PerkinElmer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $67.92.

PerkinElmer Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.